The suboptimal nature of the absorption profiles of human insulin formulations following subcutaneous administration has prompted the development of insulin analogues better suited for therapeutic use in diabetes mellitus. A particular challenge has been to engineer long-acting agents that do not produce unduly variable responses from one injection to another. One recent approach that has met with success has been to acylate, the insulin molecule with a fatty acid, thereby enabling reversible albumin binding. The first clinically available agent of this type is insulin detemir. Pharmacological studies have established that this principle is effective in prolonging action, primarily by retarding absorption. The solubility of insulin detemir in the vial and after injection and an important buffering mechanism effected by plasma albumin binding explain a significant decrease in within-subject variability of pharmacodynamic response observed in repeat isoglycaemic clamp studies where insulin detemir was compared to other basal insulin products. Owing to the extremely high ratio of albumin-binding sites to insulin detemir molecules at therapeutic concentrations, no safety considerations have been identified pertaining to albumin binding. The insulin detemir molecule retains the molecular pharmacological properties of native human insulin, including a physiological balance between metabolic and mitogenic potencies. Thus, insulin detemir offers the promise of an improved tolerability:efficacy ratio in the clinical setting.
The rationale for a basal insulin analogue
The exogenous administration of insulin to patients with diabetes mellitus has prolonged the life of millions over a period approaching 80 y. Nevertheless, effective glycaemic control remains elusive 1 and diabetes is still associated with a high burden of morbidity and premature mortality, devastating quality of life for its sufferers and their relatives. 2 The primary limiting factor in the treatment of diabetes is our inability to repair or reproduce the physiological mechanisms that regulate nutrients, most notably the dynamic insulin responses that in health mediate blood glucose homeostasis.
The most practical route for therapeutic insulin administration is via subcutaneous injection or infusion, but the absorption of insulin into the circulation from a subcutaneous depot is a crude and unphysiological method of insulin replacement. 3 In health, insulin secretion into the portal vein is continuously modulated in response to nutrient and other stimuli to regulate hepatic glucose output, and other metabolic processes such as peripheral glucose uptake and lipogenesis. Insulin is produced in pancreatic beta cells, where at high concentration in the presence of zinc ions it self-associates into hexamers for efficient storage within vesicles. 4 Dilution upon exocytosis causes immediate dissociation of insulin hexamers into biologically active monomers. The dynamic profile of insulin secretion is characterised by a low and constant 'basal' output, most clearly seen overnight, with rapidly produced elevations of output triggered by prandial stimuli. 5, 6 The clinical challenge is to reproduce this profile via subcutaneous absorption of exogenous insulin. The problem is that pharmaceutical formulations of human insulin must be of a concentration in which insulin is hexameric if they are to be therapeutically useful, that is, of acceptable physical stability and of tolerable injection volume. Following injection, dilution of the insulin depot is relatively slow, hence so too is dissociation into monomers. 7, 8 Self-associated insulin is slower to diffuse through the tissue and penetrate the capillary wall than monomeric insulin, 9 and the rate of entry into the systemic circulation is dependent on local environmental factors such as blood flow rate. This means that the plasma kinetic profile of injected human insulin resembles neither the basal nor prandial profiles of normal physiology, and that the pharmacokinetic profiles that follow standardised injections vary both between and within individuals. [10] [11] [12] [13] Ideally, the absorption properties of subcutaneously injected insulin need to be modified so as to produce both rapidly absorbed preparations (to replace endogenous prandial insulin) and preparations with slow and steady absorption rates (to replace basal insulin secretion), with a further goal being predictability in absorption rate profile from injection to injection.
Attempts to achieve these goals have met with mixed success. A greater knowledge of the domains of the insulin molecule involved in receptor interaction and self-association, 14 combined with recombinant DNA technology, enabled the molecular structure of insulin to be modified to produce 'weakly' self-associating analogues of human insulin in the 1980s and 1990s. 9, 15 Thus, the prandial agents, insulin aspart and insulin lispro, were developed in which dissociation rate constants are increased relative to human insulin. These rapidly dissociating analogues are absorbed faster than human insulin from the subcutaneous depot, so that they are better able to mimic the prandial insulin secretion profiles of normal physiology. [16] [17] [18] During the course of development of these analogues, however, it was discovered that even minor changes in the amino-acid sequence of insulin could change the molecular ternary structure so as to affect receptor interactions and hence metabolic and mitogenic activity. A prototype analogue, insulin X10 (or B10 aspart) was shown to have a greatly increased IGF-I receptor:insulin receptor affinity ratio compared to human insulin, as well as increased residence time at the insulin receptor. At high doses, this analogue was carcinogenic in female Sprague-Dawley rats. [19] [20] [21] Thus, the importance of testing the full pharmacodynamic profile of insulin analogues was highlighted. Success in developing insulin analogues with a protracted and predictable action has come more slowly. However, the earliest of all attempts to modify insulin absorption properties were aimed at delaying and prolonging absorption, the goal being to decrease injection frequency. Pharmaceutical formulations in which protamine (neutral protamine Hagedorn (NPH)) or an excess of zinc (Lente, Ultralente insulin) were added were designed to form suspensions that would slowly dissolve once injected. Preformed precipitates, however, require thorough resuspension before injection to ensure the correct insulin concentration. Incomplete resuspension by patients has been shown to be a major source of variability. [22] [23] [24] Furthermore, even the mean absorption profiles of these conventional basal insulins are far from ideal. 23 NPH insulin, for example, is characterised by a peak in the pharmacokinetic profile 4-6 h after injection followed by a steady decline, rather than a low and constant absorption. 25 The combination of a peak in effect and the unpredictability of the time and extent of this peak inevitably incurs a risk of hypoglycaemia, and as basal insulins are often dosed in the evening there is a real risk of nocturnal hypoglycaemia. This limits the tolerable dose and has led to the search for basal insulin analogues with improved pharmacokinetic and pharmacodynamic properties.
Strategies in the search for an improved basal insulin analogue Three strategies have been followed in the Novo Nordisk drug discovery laboratories. The first principle was to modify the amino-acid sequence so as to shift the isoelectric point of the insulin analogue towards neutrality, reducing solubility at physiological pH values. With this strategy, the resulting analogue can be formulated in an acidic medium and injected as a solute, thereby avoiding the need for resuspension. In the neutral subcutaneous environment, the insulin will precipitate and the solid phase will then dissolve slowly to give protracted absorption. The unpredictable nature of the formation and redissolution of a precipitate might, however, introduce another source of variability. 26 Indeed, the prototype analogues based on this principle were not developed clinically because of low bioavailability and variability of action. 27, 28 Nevertheless, this principle was successfully used in later years to produce insulin glargine (Gly A21 Arg B31 Arg B32 human insulin), in which two arginine residues added to the C-terminus of the B-chain shift the isoelectric point from pH 5.4 to 6.7.
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A second strategy aimed at producing an improved basal insulin was to engineer a stable hexamer by substituting the zinc ions situated in the core of the hexameric structure with cobalt ions. 30, 31 This complex, named Co(III)insulin, was found to be absorbed slowly as a hexamer and then undergo enzymatic cleavage into monomers in the circulation. However, it offered no pharmacological advantages over NPH insulin. The most recent strategy, culminating in the clinical availability of insulin detemir, has been to acylate fatty acids to the insulin molecule so as to stabilise self-association and permit reversible insulin-albumin binding. 32, 33 This principle allows for a neutral liquid preparation to be made that does not precipitate at any stage in the administrationabsorption process and so avoids important sources of variability. Insulin detemir (Lys B29 (N-tetradecanoyl)des (B30)human insulin) is formed by the removal of the amino acid threonine at the B30 locus, with a 14-carbon fatty acid (myristic acid) being acylated to lysine at locus B29.
The unique mode of protraction of insulin detemir
The mechanism of protraction of insulin detemir has been investigated in physicochemical and pharmacological studies. 34 Insulin detemir was compared to various acylated and nonacylated analogues (differing in their self-association profiles and albumin affinity) in a series of size-exclusion chromatography experiments, manipulating the eluent to simulate chemical changes at the injection depot. While
Insulin analogues for therapeutic use in diabetes mellitus P Kurtzhals insulin detemir is hexameric upon injection, the data suggest that it then forms a hexamer-dihexamer equilibrium, with dihexamers formed by contact between myristic acid groups, situated at the poles of each hexameric complex ( Figure 1 ). 35 This increase in self-association state in the depot is thought to occur as pharmaceutical preservatives (phenol and cresol) equilibrate with physiological electrolytes. Size-exclusion chromatography also showed that both self-associated (dihexameric, hexameric and dimeric) and monomeric insulin detemir will bind to albumin. Thus, there are two mechanisms by which insulin detemir might be retained in the injection depot. Studies of disappearance rates of radiolabelled insulin analogues in porcine models were used to gauge the relative importance of self-association and albumin binding in depot protraction. 34 Here, a T 50% disappearance time of 10.2 h for insulin detemir was longer than the T 50% values of an acylated monomer (2.9 h), an acylated weakly associating hexamer (6.9 h) and an acylated stable hexamer (8.8 h), implying that self-association is an important factor in the slow absorption of insulin detemir. On the other hand, the T 50% of the albumin-binding acylated stable hexamer (and insulin detemir) was much longer than that of the stable nonbinding hexamer, Co(III)insulin (2.8 h), indicating that albumin binding also delays absorption. Thus, the likely mechanism of protracted absorption is self-association of insulin detemir causing retention in the depot for long enough to establish albumin binding, which further delays absorption.
As insulin detemir also binds reversibly to albumin in the circulation, it could be speculated that further protraction of the pharmacodynamic effect might occur through retention in the plasma compartment. However, comparisons of plasma residence times with other acylated analogues with differing albumin-binding affinities suggest that while there is some retention of insulin detemir in the circulation, the contribution of this to the overall protraction of action is much lower than that attributable to depot retention.
Plasma albumin binding: a mechanism for buffering against variable absorption
In the circulation, insulin detemir is 98% albumin bound, 32, 33 and this property has been calculated to give rise to two potentially clinically important buffering effects. 36 First, the absorption rate of insulin detemir is only slightly affected by variations in blood flow rate at the injection site. This is because the absorption rate mainly depends on the concentration difference of free insulin between the interstice and the capillary as insulin can diffuse both into and out of the capillary lumen. For human insulin, the capillary concentration is relatively high and flow dependent. A high flow will decrease the capillary concentration and increase the absorption rate. Similarly, a low flow will decrease the concentration difference and the absorption rate. In contrast, absorbed insulin detemir is immediately and almost completely bound by circulating albumin in the capillary lumen, so the free concentration is kept very low and albumin-bound detemir complexes are too large to readily re-exit the capillary. Thus, the free concentration difference effectively becomes more or less constant and independent of the flow rate. Second, data from pharmacokinetic experiments in dogs describing half-lives in different tissues as well as transcapillary transport [37] [38] [39] predict that even if the plasma concentration of insulin detemir were to rise, the effect of this at target tissues would be reduced. This is because only 2% of circulating insulin detemir is unbound and available for transcapillary transport, and hence the equilibration of distal interstitial concentrations with plasma concentrations. Thus, changes in plasma concentration are slow to affect target tissue interstitial concentrations, whereas there will be an almost immediate increase in the interstitial concentration should circulating insulin levels rise (Figure 2 ). These two buffering properties might explain a significant reduction in the within-subject variability of pharmacokinetic and pharmacodynamic profiles from injection to injection seen in comparison to more conventional basal insulins. Insulin analogues for therapeutic use in diabetes mellitus P Kurtzhals
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An important consideration with the reversible albuminbinding principle is whether it might pose a risk of interaction with other albumin-bound compounds. In fact, the molar serum concentration of insulin detemir barely reaches 1:50 000 that of albumin when given in therapeutic doses, and as there are at least eight fatty acid-binding sites on each albumin molecule, it follows that only a small fraction of binding sites will be occupied. The potential of insulin detemir to interact competitively with other albumin-bound drugs has nevertheless been studied in vitro, and at drug:albumin concentration ratios as high as 1:1, there were no interactions between insulin detemir and a series of free fatty acids, nor with phenylbutazone, warfarin, ibuprofen, diazepam, tolbutamide, glibenclamide, aspirin or valproate.
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Insulin detemir at the level of the receptor
The receptor interaction profile of insulin detemir has been studied in several in vitro cell models. 21, 43 Insulin detemir has been shown to act as a full agonist of the insulin receptor using lipogenesis and glucose utilisation assays in rat and human adipocytes, respectively. 43 Although the molar potency of insulin detemir was about 10% that of human insulin in these systems, insulin detemir nevertheless evoked 100% maximal responses equivalent to human insulin, with parallel dose-response curves. In vivo, a reduced receptor affinity should not affect molar potency, because the physiological clearance of insulin is predominantly via its receptor. Therefore, a reduced affinity will merely result in a reduced rate of clearance, with plasma and interstitial insulin concentrations simply rising to 'compensate'. In fact, in vivo pharmacodynamic (and clinical) studies have shown that insulin detemir does have a reduced molar potencyFabout 25% that of human insulin. 44, 45 This is probably due to a relatively reduced rate of access from the plasma compartment to the interstitial fluid with an increased rate of nonreceptor-mediated clearance. 46 Consequently, insulin detemir is marketed in a formulation that is four times the molar strength of human insulin so as to maintain parity in unit doses and injection volumes. A further series of experiments sought to investigate the safety profile of insulin detemir at the receptor/cellular level in comparison to other insulin analogues. 21 Receptor affinities were measured using purified human insulin receptors, receptor dissociation rates were determined using Chinese hamster ovary cells overexpressing human insulin receptors, metabolic potencies were evaluated using primary mouse adipocytes and mitogenic potencies were determined in human osteosarcoma cells. Receptor residence time and the relative affinity for the IGF-I receptor were not increased for insulin detemir relative to human insulin, hence insulin detemir did not display an increased mitogenic potency ( Table 1) .
The pharmacokinetic and pharmacodynamic profile of insulin detemir
This pharmacokinetic and glucose-lowering time-action profile of subcutaneously injected insulin detemir has been assessed comparatively in 24-h isoglycaemic clamp studies. 40, 45 In a randomised, double-blind, six-period crossover study, 12 people with type I diabetes were given single injections of insulin detemir at doses of 0.1, 0.2, 0.4, 0.8 and 1.6 U/kg (1 U ¼ 24 nmol) as well as an injection of 0.3 IU/kg NPH insulin (1 IU ¼ 6 nmol). 45 The dose-response relationships for pharmacokinetic and pharmacodynamic measures were linear, and at the higher doses, the measurable duration of action of insulin detemir exceeded 24 h. Insulin detemir was shown to have an equivalent total blood glucose-lowering action to NPH insulin on a unit basis, but with a longer duration of action and reduced maximal effect (Table 2) . At a dose of 0.4 U/kg (a typical therapeutic dose), the mean duration of action was 20 h, suggesting that many patients will be able to dose insulin detemir once daily. Another pharmacodynamic study specifically assessed the within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine. 40 In this parallel-group, randomised, double-blind, euglycaemic (5.5 mmol/l) clamp study of 54 people with type I diabetes, each participant received four injections of one of the comparator insulins (0.4 U/kg), these being given on four different occasions. The 24-h glucose infusion rate (GIR) time-action profiles were significantly more consistent across the four insulin detemir injections (CV for GIR AUC , 27%) when compared to both insulin glargine (CV, 48%, Po0.001) and NPH insulin (CV, 68%, Po0.001). Lower within-subject variability was also found with insulin detemir for GIR max , the respective CVs Other pharmacological studies have shown that insulin detemir is more consistent in its pharmacokinetic profile across-and within-age groups than NPH insulin, 47 and that the pharmacokinetic profile is unaffected by renal or moderate hepatic impairment. 48 Furthermore, dialysis appears to result in negligible elimination of insulin detemir.
Summary
In summary, a thorough programme of pharmacological assessment of insulin detemir has suggested that acylation of the insulin molecule to enable albumin binding is an effective principle for engineering protraction and predictability, with a good safety profile. Protraction is achieved primarily through retention in the injection depot, with plasma albumin binding mediating an important buffering mechanism. This, together with the avoidance of precipitation, might underpin the remarkably low within-subject variability seen in repeat glucose clamp studies. The obvious advantage that the smooth and flat kinetic profile with reduced variability should bring to the clinical arena is a reduced risk of hypoglycaemia, which in turn should allow more aggressive titration towards lower glycaemic targets. The data suggest that at equivalent unit doses, insulin detemir would have a longer duration of action with less of a peak effect. Data from Pieber et al.
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